A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

被引：4
|
作者：
DiNardo, Courtney D.
Kantarjian, Hagop M.
Ravandi, Farhad
Konopleva, Marina
Kadia, Tapan M.
Borthakur, Gautam
Daver, Naval G.
Durand, Mends
Rivera, Silvia
Quintas-Cardama, Alfonso
Garcia-Manero, Guillermo
Cortes, Jorge E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2698.2698
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2698
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [32] A pilot study of bendamustine in elderly patients with high-risk MDS and AML
    Strupp, C.
    Knipp, S.
    Hartmann, J.
    Gattermann, N.
    Haas, R.
    Germing, U.
    LEUKEMIA & LYMPHOMA, 2007, 48 (06) : 1161 - 1166
  • [33] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML)
    Jabbour, E.
    Faderl, S.
    Ravandi, F.
    Konopleva, M.
    Verstovsek, S.
    Cortes, J.
    Wierda, W.
    Newsome, W. M.
    Yang, H.
    Kantarjian, H.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    Garcia-Manero, G.
    Yang, A. S.
    Klimek, V.
    Luger, S.
    Newsome, W. M.
    Berman, N.
    Patterson, T.
    Maroun, C.
    Li, Z.
    Ward, R.
    Martell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
    S Ettou
    E Audureau
    C Humbrecht
    B Benet
    H Jammes
    T Clozel
    V Bardet
    C Lacombe
    F Dreyfus
    P Mayeux
    E Solary
    M Fontenay
    Leukemia, 2012, 26 : 2297 - 2299
  • [36] Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
    Ettou, S.
    Audureau, E.
    Humbrecht, C.
    Benet, B.
    Jammes, H.
    Clozel, T.
    Bardet, V.
    Lacombe, C.
    Dreyfus, F.
    Mayeux, P.
    Solary, E.
    Fontenay, M.
    LEUKEMIA, 2012, 26 (10) : 2297 - 2299
  • [37] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    Ossenkoppele, G. J.
    Breems, D. A.
    Stuessi, G.
    Van Norden, Y.
    Bargetzi, M.
    Biemond, B. J.
    A von dem Borne, P.
    Chalandon, Y.
    Cloos, J.
    Deeren, D.
    Fehr, M.
    Gjertsen, B.
    Graux, C.
    Huls, G.
    Janssen, J. J. J. W.
    Jaspers, A.
    Jongen-Lavrencic, M.
    De Jongh, E.
    Klein, S. K.
    Van der Klift, M.
    Van Marwijk Kooy, M.
    Maertens, J.
    Micheaux, L.
    Van der Poel, M. W. M.
    Van Rhenen, A.
    Tick, L.
    Valk, P.
    Vekemans, M. C.
    Van der Velden, W. J. F. M.
    De Weerdt, O.
    Pabst, T.
    Manz, M.
    Lowenberg, B.
    Havelange
    Vekemans, M-C
    Moors, I.
    Van Obberg, F.
    Maertens, J. A.
    Hodossy, B.
    Vansteenweghen, S.
    Lammertijn, L.
    Sonet, A.
    Triffet, A.
    Gjertsen, B. T.
    Passweg, J.
    Heim, D.
    Giovanni, San
    Stuessi, Georg
    Betticher, D.
    Chalandon, Y.
    LEUKEMIA, 2020, 34 (07) : 1751 - 1759
  • [38] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    G. J. Ossenkoppele
    D. A. Breems
    G. Stuessi
    Y. van Norden
    M. Bargetzi
    B. J. Biemond
    P. A von dem Borne
    Y. Chalandon
    J. Cloos
    D. Deeren
    M. Fehr
    B. Gjertsen
    C. Graux
    G. Huls
    J. J. J. W. Janssen
    A. Jaspers
    M. Jongen-Lavrencic
    E. de Jongh
    S. K. Klein
    M. van der Klift
    M. van Marwijk Kooy
    J. Maertens
    L. Michaux
    M. W. M. van der Poel
    A. van Rhenen
    L. Tick
    P. Valk
    M. C. Vekemans
    W. J. F. M. van der Velden
    O. de Weerdt
    T. Pabst
    M. Manz
    B. Löwenberg
    Leukemia, 2020, 34 : 1751 - 1759
  • [39] Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
    G Bug
    A Burchert
    E-M Wagner
    N Kröger
    T Berg
    S Güller
    S K Metzelder
    A Wolf
    S Hünecke
    P Bader
    J Schetelig
    H Serve
    O G Ottmann
    Leukemia, 2017, 31 : 2523 - 2525
  • [40] Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
    Bug, G.
    Burchert, A.
    Wagner, E-M
    Kroeger, N.
    Berg, T.
    Gueller, S.
    Metzelder, S. K.
    Wolf, A.
    Huenecke, S.
    Bader, P.
    Schetelig, J.
    Serve, H.
    Ottmann, O. G.
    LEUKEMIA, 2017, 31 (11) : 2523 - 2525
12345